NASDAQ$HUMA
Humacyte Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Humacyte reported financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments.
Humacyte completed its business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds. The company progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™) and other engineered tissue platform applications.
- Completed business combination with Alpha Healthcare Acquisition Corp.
- Raised $242M in proceeds.
- Progressed advanced-stage clinical- and early-stage programs of the human acellular vessel (HAV™).
- Company is laying a strong foundation of clinical, technical and infrastructure progress to support continued advancement toward commercialization.
Headline financials
Revenue & EPS history
Humacyte · Revenue · Quarterly
$241K
Forward guidance
Humacyte is focused on advancing its bioengineered tissue platform to create novel human acellular tissues and organs and transition to a public company.
Tailwinds
- Advancing bioengineered tissue platform.
- Creating novel human acellular tissues and organs.
- Transitioning to a public company.
- Laying a strong foundation of clinical progress.
- Laying a strong foundation of technical progress.
Headwinds
- Impact of COVID-19 on Humacyte’s business.
- Changes in applicable laws or regulations.
- Possibility that Humacyte may be adversely affected by other economic factors.
- Possibility that Humacyte may be adversely affected by other business factors.
- Possibility that Humacyte may be adversely affected by competitive factors.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+5.1%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+3.5%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+37.0%
Q2 2023
Best reaction
-30.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +22.9% | -1.5% | +15.2% | |
| Q4 2025 | -15.1% | -25.1% | -33.0% | |
| Q3 2025 | -3.2% | -11.7% | +2.3% | |
| Q2 2025 | -30.1% | -24.2% | -40.3% | |
| Q1 2025 | +19.5% | +23.8% | +25.4% | |
| Q4 2024 | -2.5% | -27.4% | -28.4% | |
| Q3 2024 | +4.9% | +1.5% | -8.2% | |
| Q1 2024 | +21.2% | +43.1% | +60.8% | |
| Q4 2023 | -12.8% | -13.9% | +2.8% | |
| Q3 2023 | +7.3% | +9.1% | +27.9% | |
| Q2 2023 | +37.0% | +8.9% | +19.0% | |
| Q1 2023 | -6.1% | -2.5% | +1.1% | |
| Q4 2022 | +4.9% | -1.3% | +7.1% | |
| Q3 2022 | +2.2% | -5.4% | -4.5% | |
| Q2 2022 | +8.6% | +9.1% | +2.5% | |
| Q1 2022 | -9.5% | -12.7% | -18.8% | |
| Q4 2021 | +14.1% | +12.2% | +16.5% | |
| Q2 2021 | +14.1% | +12.2% | +16.5% | |
| Q3 2021 | +9.0% | +18.4% | +4.0% | |
| Q1 2021 | +0.0% | +0.0% | +4.9% | |
| Q4 2020 | +21.2% | +28.4% | +1.5% | |
| Q3 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro